InMed Pharmaceuticals Inc (NASDAQ:INM) — Market Cap & Net Worth
Market Cap & Net Worth: InMed Pharmaceuticals Inc (INM)
InMed Pharmaceuticals Inc (NASDAQ:INM) has a market capitalization of $2.00 Million ($2.00 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29676 globally and #5787 in its home market, demonstrating a -6.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying InMed Pharmaceuticals Inc's stock price $0.71 by its total outstanding shares 2804186 (2.80 Million). Analyse InMed Pharmaceuticals Inc (INM) cash conversion ratio to see how efficiently the company converts income to cash.
InMed Pharmaceuticals Inc Market Cap History: 2015 to 2026
InMed Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $5.32 Billion to $2.00 Million (-53.39% CAGR).
Index Memberships
InMed Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #888 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2819 of 3165 |
Weight: InMed Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
InMed Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how InMed Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.60x
InMed Pharmaceuticals Inc's market cap is 0.60 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $113.29 Million | $1.09 Million | -$18.60 Million | 103.99x | N/A |
| 2023 | $23.33 Million | $4.14 Million | -$7.95 Million | 5.64x | N/A |
| 2024 | $13.29 Million | $4.60 Million | -$7.68 Million | 2.89x | N/A |
| 2025 | $2.97 Million | $4.94 Million | -$8.16 Million | 0.60x | N/A |
Competitor Companies of INM by Market Capitalization
Companies near InMed Pharmaceuticals Inc in the global market cap rankings as of May 2, 2026.
Key companies related to InMed Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
InMed Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, InMed Pharmaceuticals Inc's market cap moved from $5.32 Billion to $ 2.00 Million, with a yearly change of -53.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.00 Million | -32.59% |
| 2025 | $2.97 Million | -77.64% |
| 2024 | $13.29 Million | -43.03% |
| 2023 | $23.33 Million | -79.41% |
| 2022 | $113.29 Million | -93.83% |
| 2021 | $1.84 Billion | -60.18% |
| 2020 | $4.61 Billion | -44.61% |
| 2019 | $8.33 Billion | -29.41% |
| 2018 | $11.80 Billion | -76.06% |
| 2017 | $49.28 Billion | +526.47% |
| 2016 | $7.87 Billion | +47.83% |
| 2015 | $5.32 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of InMed Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.00 Million USD |
| MoneyControl | $2.00 Million USD |
| MarketWatch | $2.00 Million USD |
| marketcap.company | $2.00 Million USD |
| Reuters | $2.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufactur… Read more